TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 10/03/23

Experts Reviewed Data from QDENGA’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 Participants WHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGA in Public Vaccination Programs in the Coming Months De...

Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data Canada NewsWire TORONTO , Oct. 3, 2023 /CNW/ - Today, Takeda Canada Inc. ("Takeda") announced the launch of Clinical Trials (CT) Lexicon, an innovative ...

2023-10-02 17:08:28 ET Japanese pharmaceutical giant Takeda ( NYSE: TAK ) on Monday said it would voluntarily withdraw its lung cancer drug Exkivity from the U.S. market. U.S.-listed shares of TAK were down 4.9% to $14.53 after hours. The U.S. Food and Drug Administ...

Takeda ( TSE:4502/NYSE:TAK ) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY ® (mobocertinib) in the U.S. for adult patients with epidermal growth factor recep...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announced that Takeda ( TSE:4502/​NYSE:TAK ) has submitted a New Drug Application (“...

2023-09-28 16:30:23 ET More on Teva, Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Teva: Focus On Innovation And Growth Means The Times They Are A Changing Eli Lilly benefits as judge overturns $176.5M verdict in Teva patent case Novar...

2023-09-27 16:57:55 ET More on Takeda Pharmaceutical Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) ImmunoGen inks deal with Takeda for cancer drug Elahere Takeda pulls marketing application for dengue vaccine in the U.S. Seeking Alph...

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous...

2023-09-25 14:56:13 ET Extending a sharp decline from last week, Morphic Holding ( NASDAQ: MORF ) continued to trade lower Monday as BTIG downgraded the biotech, citing questions on the potential of its lead asset, MORF-057, targeted at ulcerative colitis (UC). The analyst Jul...

Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] CUVITRU is Takeda’s First Subcutaneous Immunoglobulin Plasma Therapy in Japan, Delivering on the...